Brief by Shorts91 Newsdesk / 05:34am on 02 Sep 2025,Tuesday India Global
Trump administration proposes up to 200% tariffs on imported medicines under national security provisions, potentially ending duty-free drug imports. Officials cite COVID-19 pandemic shortages and import dependence as strategic vulnerabilities requiring domestic manufacturing boost. Analysts warn of 10-14% drug price increases even with 25% tariffs, particularly affecting low-income households and generics comprising 90% of US prescriptions. India, a major generic medicine supplier, currently remains "excluded" from immediate enforcement due to crucial role in affordable American healthcare. Legal challenges emerge as appeals court rules Congressional approval needed for sweeping measures. While pharmaceutical giants invest billions in US operations, experts warn rebuilding domestic supply chains will be expensive and slow, ultimately raising patient costs significantly. (PC: Hindustan Times)
